This result indicated that the inhibition of ovarian cancer cell proliferation induced by cisplatin may be partially regulated by BTG2, and the absence of BTG2 expression may reduce the chemosensitivity of ovarian cancer cells. This evidence concerns the gene BTG2 and ovarian cancer.